- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01594918
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
This is a Phase I, open label, dose-finding, multicenter clinical trial to establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of cabazitaxel (25 mg/m2 IV q21 days) in combination with mitoxantrone (4-12 mg/m2 IV q21 days) and prednisone (5mg orally BID) in patients with metastatic CRPC who have not undergone prior chemotherapy for metastatic disease.
Up to five cohorts will be enrolled to determine the MTD and DLT profile of this combination. An accelerated titration design method is being used in order to minimize the number of patients exposed to subtherapeutic doses of mitoxantrone.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259
- Mayo Clinic
-
-
California
-
San Francisco, California, Estados Unidos, 94115
- UCSF Comprehensive Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
1. Histologically confirmed adenocarcinoma of the prostate.
2. Progressive metastatic prostate cancer (positive bone scan or measurable disease) despite castrate levels of testosterone (either from orchiectomy or LHRH agonist therapy).
3. Patients may have either non-measurable disease OR measurable disease
4. All patients must have a PSA ≥ 2 ng/mL.
5. Progressive disease based on any one of the following:
- transaxial imaging
- a rise in PSA
radionuclide bone scan
Patients whose sole manifestation of progression is an increase in disease-related symptoms are not eligible.
- For patients with measurable disease, progression will be defined by the RECIST criteria.
- For patients with non-measurable disease, a positive bone scan and elevated PSA will be required. PSA evidence for progressive prostate cancer during or after first-line chemotherapy consists of a PSA level of at least 2 ng/ml which has risen on at least 2 successive occasions, at least one week apart. If the confirmatory PSA (#3) value is less (i.e., #3b) than the screening PSA (#2) value, then an additional test for rising PSA (#4) will be required to document progression for the purposes of eligibility.
Radionuclide bone scan: new metastatic lesions
6. Testosterone < 50 ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
7. ECOG Performance Status 0 -2.
8. Required Laboratory values:
- Creatinine < 1.5 x upper limits of normal (ULN). If Cr. > 1.5 x ULN, then calculated creatinine clearance > 40cc/min.
- ALT and AST within normal limits
- Absolute neutrophil count > 2,000/mm3
- Platelets > 100,000/ mm3
- Hemoglobin > 8.0 gm/dL
Total bilirubin within normal limits
9. Ejection fraction by MUGA scan or echocardiogram ≥ lower limit of institutional normal.
10. Patients receiving hormonal therapy (i.e. any dose of megestrol acetate (Megace), Proscar (finasteride), any herbal product known to decrease PSA levels (e.g., Saw Palmetto and PC-SPES) other than LHRH agonist/antagonist or a stable dose of corticosteroid from a prior chemotherapy regimen must discontinue the agent for at least 4 weeks prior to enrollment. Progressive disease must be documented after discontinuation of the hormonal therapy.
11. No other systemic therapies for prostate cancer within 28 days prior to initiation of this protocol.
12. Prior radiation therapy completed ≥ 4 weeks prior to enrollment.
13. No history of radiopharmaceuticals (strontium, samarium) for prostate cancer treatment.
14. Patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. Should a patient's sexual partner become pregnant or suspect she is pregnant while the patient is participating in this study, he should inform the treating physician immediately.
15. Life expectancy > 12 weeks.
16. Age ≥ 18 years
17. Inclusion of Minorities: Men and members of all ethnic groups are eligible for this trial.
Exclusion Criteria:
- Patients with significant cardiovascular disease including congestive heart failure (NYHA class III or IV), active angina pectoris or myocardial infarction within 6 months.
- Patients with serious intercurrent infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy.
- Patients with psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with pre-existing neuropathy greater than CTCAE Grade 1 (motor or sensory).
- Patients with known prior severe hypersensitivity reactions to cabazitaxel or other agents containing polysorbate 80.
- Patients with known active brain metastases are excluded because of their poor prognosis. Head CT is NOT routinely required prior to enrollment. Patients with treated, asymptomatic brain metastasis will be eligible for enrollment.
- Patients with a "currently active" second malignancy other than non-melanoma skin cancer are excluded. [Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.]
- Concurrent use of moderate to strong CYP3A4 inhibitors is not allowed.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Cabazitaxel, Mitoxantrone, Prednisone
|
25 mg/m2 or 20 mg/m2, IV, once every 21 days
Outros nomes:
4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
Outros nomes:
5 mg PO BID
6 mg, SC, once every 21 days
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Determination of the maximum tolerated dose (MTD) of the combination of cabazitaxel and mitoxantrone/prednisone as chemotherapy for patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.
Prazo: Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Dose Limiting Toxicity (DLT)
Prazo: Participants will have AE/Toxicity evaluations every 21 days. Average study participation is approximately 4 months.
|
Number of Grade 3 or greater non-hematologic toxicity recorded.
|
Participants will have AE/Toxicity evaluations every 21 days. Average study participation is approximately 4 months.
|
Reduction in Prostate Specific Antigen (PSA), of the combination of cabazitaxel and mitoxantrone/prednisone in patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.
Prazo: Participants will have PSA assessments every 21 days. Average study participation is approximately 4 months.
|
Participants will have PSA assessments every 21 days. Average study participation is approximately 4 months.
|
|
Efficacy of drug combination including objective response rate and duration of response
Prazo: Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Rahul Aggarwal, MD, University of California, San Francisco
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias Genitais Masculinas
- Doenças prostáticas
- Neoplasias prostáticas
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes do Sistema Nervoso Periférico
- Inibidores Enzimáticos
- Analgésicos
- Agentes do Sistema Sensorial
- Antiinflamatórios
- Agentes Antineoplásicos
- Glicocorticóides
- Hormônios
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Agentes Antineoplásicos Hormonais
- Inibidores da Topoisomerase II
- Inibidores da Topoisomerase
- Prednisona
- Mitoxantrona
Outros números de identificação do estudo
- UCSF Protocol No. 11951
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Cabazitaxel
-
Jeffrey Yachnin M.D., PhD.SanofiConcluídoCâncer de Próstata Metastático Resistente à CastraçãoSuécia
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiConcluídoCarcinoma Espinocelular de Cabeça e PescoçoEstados Unidos
-
Azienda Socio Sanitaria Territoriale degli Spedali...San Luigi Gonzaga HospitalDesconhecido
-
Vejle HospitalSanofiRescindido
-
Institut für Klinische Krebsforschung IKF GmbH...ConcluídoEstudo com cabazitaxel em pacientes previamente tratados com câncer gástrico avançado ou metastáticoCâncer de intestinoAlemanha
-
Gustave Roussy, Cancer Campus, Grand ParisSanofiDesconhecidoTumores de Células Germinativas Não SeminomatososFrança
-
Rambam Health Care CampusConcluídoCarcinoma UrotelialIsrael
-
Hellenic Cooperative Oncology GroupSanofiConcluídoCâncer de próstata metastático ósseoGrécia
-
M.D. Anderson Cancer CenterSanofiRetiradoCancer cerebral
-
University Hospitals Bristol and Weston NHS Foundation...SanofiConcluído